Jan Rothenburger

This inventor holds 6 USPTO granted patents and 3 published patent applications, plus 1 CIPO patent and 2 EPO patents. Top assignee: Sanochemia Pharmazeutika Ag. Active years: 2008-2017.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jan Rothenburger. Retrieved from https://idiyas.com/inventor/jan-rothenburger

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 6 (Patent Applications = 3)

% Patents Active = 83.3

CIPO Patents = 1

EPO Patents = 2 (Patent Applications = 3)

Average Co-Inventor Count = 5.4

ph-index = 2

Forward Citations = 10(Granted Patents)

Company Filing History:

6 out of 15

Sanochemia Pharmazeutika Ag

patents

Years Active: 2008-2017

Loading Chart...

6 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9675598 - Compositions of tolperisone (2017-06-13),

2. 9662317 - Methods of administering tolperisone for therapeutic purposes (2017-05-30),

3. 9315480 - Compositions of tolperisone (2016-04-19),

4. 8372979 - Process for the production of high-purity 2,4'-dimethyl-3-piperidino-propiophenone (tolperisone), pharmaceutical compositions that contain the latter, as well as active ingredient formulations that contain tolperisone (2013-02-12),

5. 8212029 - Method for the production of high-purity 4a, 5, 9, 10, 11, 12,-hexahydro-6H-benzofuro [3a, 3, 2-ef] [2] benzazepine, and the derivatives thereof (2012-07-03),

6. 7385060 - Method for producing salts of tolperisone (2008-06-10),

Title: Jan Rothenburger: Innovator in Pharmaceutical Compositions

Introduction

Jan Rothenburger is a notable inventor based in Oslip, Austria. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compositions related to tolperisone. With a total of six patents to his name, Rothenburger's work has the potential to impact therapeutic practices significantly.

Latest Patents

Rothenburger's latest patents include innovative methods and compositions involving tolperisone. One of his patents focuses on tolperisone, or a pharmaceutically acceptable salt or hydrate thereof, with 10 ppm 2-methyl-1-(4-methylphenyl)-propenone (4-MMPPO) or less. This patent outlines methods of producing tolperisone while limiting exposure to tolerable levels of 4-MMPPO. Another significant patent details methods of administering tolperisone to subjects in need, emphasizing the importance of minimizing exposure to 4-MMPPO during treatment.

Career Highlights

Rothenburger is currently associated with Sanochemia Pharmazeutika AG, where he continues to advance his research and development efforts. His work in the pharmaceutical industry has been instrumental in creating safer and more effective treatment options for patients.

Collaborations

Rothenburger collaborates with esteemed colleagues such as Stefan Welzig and Klaus Gerdes. Their combined expertise contributes to the innovative environment at Sanochemia Pharmazeutika AG.

Conclusion

Jan Rothenburger is a prominent figure in the pharmaceutical industry, known for his innovative work on tolperisone compositions. His contributions through patents and collaborations highlight his commitment to improving therapeutic methods.

Profile summary based on public USPTO records.